Table 1.

Characteristics of trials included in the DelibeRATE study ^a

Trial characteristics	Trial 1	Trial 2	Trial 3
Clinical condition	Vaginal prolapse	Haemorrhoids	Ureteric stones
Trial design	RCT and comprehensive cohort	Simple parallel design	Simple parallel design
Sample size, N (n)	4,500 (2,250 randomised)	800	1,200
Recruitment rate (%)	49	74	56
Arms	3 in each repair arm (4 different interventions)	2	3
Intervention	Surgery (RCT split by primary or secondary repair	Surgery	Drug
	Primary repair randomisation	1. Traditional excisional haemorrhoidectomy	1. Calcium channel blocker
	1. Standard repair	2. Stapled haemorrhoidopexy	2. α blocker
	2. Standard repair with biological mesh		3. Placebo
	3. Standard repair with nonabsorbable mesh
	Secondary repair randomisation
	1. Standard repair
	2. Standard repair with nonabsorbable mesh
	3. New repair with mesh kit
Blinding	Participants and outcome assessors (for patient-reported outcomes)	Participants and outcome assessors (for patient-reported outcomes)	Participants, caregivers and outcome assessors
Number of sites	15	31	24
Primary outcome (clinical or patient-reported and timing)	Patient-reported at 2 years postrandomisation	Patient-reported at 2 years postrandomisation	Clinical at 4 weeks and patient-reported at 12 weeks postrandomisation
Parent trial participant characteristics
Median age (IQR)	61 (52 to 68)	49 (20 to 40)	44 (34 to 52)
Sex (% females)	100	48	19

^aRCT, Randomised controlled trial.